J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma

Date : 07/19/2019 @ 11:45AM
Source : Dow Jones News
Stock : Halozyme Therapeutics Incorporated (HALO)
Quote : 16.6  0.0 (0.00%) @ 12:00AM

J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said is seeking approval from the European Medicines Agency for subcutaneous use of Darzalex in patients with multiple myeloma.

Darzalex is currently only approved for intravenous use.

Janssen said subcutaneous Darzalex is co-formulated with Halozyme Therapeutics Inc.'s (HALO) Enhanze drug-delivery technology.

Janssen last week filed for U.S. Food and Drug Administration approval for the subcutaneous formulation of Darzalex in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

July 19, 2019 07:30 ET (11:30 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest HALO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.